FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981819353> ?p ?o ?g. }

• W2981819353 abstract "Abstract Background Although the prescription of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (AF) has been rapidly increasing in Asian countries since their introduction, limited evidence exists on the effectiveness and safety of warfarin and all 4 available NOACs from current clinical practice in the Asian population. We aimed to evaluate comparative effectiveness and safety of warfarin and all 4 available NOACs Methods We studied a retrospective observational cohort of oral anticoagulant (OAC) naïve non-valvular AF patients treated with warfarin or NOACs (rivaroxaban, dabigatran, apixaban, or edoxaban) from January 2015 to December 2017, based on the Korean Health Insurance Review and Assessment database. For the comparisons, warfarin to 4 NOACs and NOAC to NOAC comparison cohorts were balanced using inverse probability of treatment weighting (IPTW). Ischemic stroke, intracranial hemorrhage (ICH), gastrointestinal bleeding (GIB), major bleeding (MB) and a composite clinical outcome were evaluated. Results A total of 116,804 patients were included (25,420 with warfarin, 35,965 with rivaroxaban, 17,745 with dabigatran, 22,177 with apixaban, and 15,496 with edoxaban). Patients treated with warfarin were younger (mean age 67 years) compared to NOAC users (71 to 73 years) and had lower mean CHA2DS2-VASc score (3.18) than the NOAC groups (3.58 to 3.76). Among the NOAC users, patients prescribed apixaban were older (mean age 73 years) than other NOAC groups (71 to 72 years), had higher mean CHA2DS2-VASc score (3.76) than others (3.55 to 3.63) and higher burden of comorbidities. More than half of patients were prescribed reduced dose regimes. After IPTW, all baseline covariates were well balanced across 5 treatment groups. Compared with warfarin, all NOACs were associated with lower risks of ischemic stroke, ICH, GIB, MB and composite outcome (Figure A). Apixaban and edoxaban showed a lower rate of ischemic stroke compared with rivaroxaban and dabigatran (Figure B). Apixaban, dabigatran and edoxaban had a lower rate of GIB and MB compared with rivaroxaban. The composite clinical outcome was non-significantly different for apixaban vs edoxaban. Conclusions In this large contemporary observational Asian cohort, all 4 NOACs were associated with lower rates of ischemic stroke and major bleeding compared to warfarin. Differences in clinical outcomes between NOACs may give useful guidance for physicians to choose drugs to fit their particular patient clinical profile." @default.
• W2981819353 created "2019-11-01" @default.
• W2981819353 creator A5013943013 @default.
• W2981819353 creator A5050407708 @default.
• W2981819353 creator A5055234039 @default.
• W2981819353 creator A5064081693 @default.
• W2981819353 creator A5084749591 @default.
• W2981819353 creator A5089065633 @default.
• W2981819353 creator A5089594322 @default.
• W2981819353 date "2019-10-01" @default.
• W2981819353 modified "2023-09-27" @default.
• W2981819353 title "P4782Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation" @default.
• W2981819353 doi "https://doi.org/10.1093/eurheartj/ehz745.1158" @default.
• W2981819353 hasPublicationYear "2019" @default.
• W2981819353 type Work @default.
• W2981819353 sameAs 2981819353 @default.
• W2981819353 citedByCount "0" @default.
• W2981819353 crossrefType "journal-article" @default.
• W2981819353 hasAuthorship W2981819353A5013943013 @default.
• W2981819353 hasAuthorship W2981819353A5050407708 @default.
• W2981819353 hasAuthorship W2981819353A5055234039 @default.
• W2981819353 hasAuthorship W2981819353A5064081693 @default.
• W2981819353 hasAuthorship W2981819353A5084749591 @default.
• W2981819353 hasAuthorship W2981819353A5089065633 @default.
• W2981819353 hasAuthorship W2981819353A5089594322 @default.
• W2981819353 hasConcept C126322002 @default.
• W2981819353 hasConcept C164705383 @default.
• W2981819353 hasConcept C2776301958 @default.
• W2981819353 hasConcept C2778661090 @default.
• W2981819353 hasConcept C2778810321 @default.
• W2981819353 hasConcept C2779161974 @default.
• W2981819353 hasConcept C2780290652 @default.
• W2981819353 hasConcept C2780638905 @default.
• W2981819353 hasConcept C71924100 @default.
• W2981819353 hasConceptScore W2981819353C126322002 @default.
• W2981819353 hasConceptScore W2981819353C164705383 @default.
• W2981819353 hasConceptScore W2981819353C2776301958 @default.
• W2981819353 hasConceptScore W2981819353C2778661090 @default.
• W2981819353 hasConceptScore W2981819353C2778810321 @default.
• W2981819353 hasConceptScore W2981819353C2779161974 @default.
• W2981819353 hasConceptScore W2981819353C2780290652 @default.
• W2981819353 hasConceptScore W2981819353C2780638905 @default.
• W2981819353 hasConceptScore W2981819353C71924100 @default.
• W2981819353 hasLocation W29818193531 @default.
• W2981819353 hasOpenAccess W2981819353 @default.
• W2981819353 hasPrimaryLocation W29818193531 @default.
• W2981819353 hasRelatedWork W1885252228 @default.
• W2981819353 hasRelatedWork W2095473217 @default.
• W2981819353 hasRelatedWork W2205070772 @default.
• W2981819353 hasRelatedWork W2328836860 @default.
• W2981819353 hasRelatedWork W2523933248 @default.
• W2981819353 hasRelatedWork W2620376388 @default.
• W2981819353 hasRelatedWork W2738113730 @default.
• W2981819353 hasRelatedWork W2750762793 @default.
• W2981819353 hasRelatedWork W2789972226 @default.
• W2981819353 hasRelatedWork W2889307794 @default.
• W2981819353 hasRelatedWork W2910294241 @default.
• W2981819353 hasRelatedWork W2981502991 @default.
• W2981819353 hasRelatedWork W2981926242 @default.
• W2981819353 hasRelatedWork W2983944525 @default.
• W2981819353 hasRelatedWork W3028874121 @default.
• W2981819353 hasRelatedWork W3036175486 @default.
• W2981819353 hasRelatedWork W3108416431 @default.
• W2981819353 hasRelatedWork W3109125958 @default.
• W2981819353 hasRelatedWork W3109668938 @default.
• W2981819353 hasRelatedWork W3110066773 @default.
• W2981819353 isParatext "false" @default.
• W2981819353 isRetracted "false" @default.
• W2981819353 magId "2981819353" @default.
• W2981819353 workType "article" @default.